Table of Contents
<< Previous Issue | Jul 2007 (Vol: 2007, Issue: 85) | Next Issue >> |
- Section: Business Commentaries
-
Europe United?
- Section: Cartoons
-
Adverse effect
- Section: Company Profile
-
Intendis GmbH
- Section: Deal Trackers
-
Arbelic (telavancin)
- Section: Features
-
Amgen's Reality Check
-
The Bioterrorism Threat: Smallpox Vaccine Stockpiling
-
How Companies Source Their Licensing Opportunities, Part II: The Importance of Personal Networks
-
Therapy Focus: Osteoporosis
- Section: General
-
The Therapeutic Use of Cannabinoids
- Section: Licensing
-
Synosia Licenses Parkinson’s Compound from Syngenta
-
Novacea Licences Cancer Therapy to Schering-Plough for US$452 M
- Section: Mergers & Acquisitions
-
Private Equity Consortium Buys Out Biomet with Sweetened Offer
-
Genzyme to Acquire Bioenvision
- Section: Research & Development
-
Nycomed and Micromet to Collaborate on Antibody Development
-
Lexicon Forms Development and Financing Agreement with Symphony Capital